Analysis

Capricor Therapeutics, Inc. (CAPR) Stock Analysis

Capricor Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CAPR.

websiteCAPR/analysis/CAPR

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CAPR.

Stock profile

Ticker

CAPR

Asset type

Stock

Market cap

$1.49B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Capricor Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CAPR primary listing
  • 4LN2
  • A2PLU4

Latest Capricor Therapeutics, Inc. news

Capricor Therapeutics : Expands Commercial Leadership Team

Capricor Therapeutics : Expands Commercial Leadership

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint ...

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company de...

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Mee...

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rar...

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Frank Guillemette (the "Acquiror ") announces that, on March 18, 2026, he acquired an aggregate of 957,000 common shares in...

Research sections

Valuation

Review valuation context for Capricor Therapeutics, Inc..

Future growth

Review future growth context for Capricor Therapeutics, Inc..

Past performance

Review past performance context for Capricor Therapeutics, Inc..

Financial health

Review financial health context for Capricor Therapeutics, Inc..

Dividend

Review dividend context for Capricor Therapeutics, Inc..

Management

Review management context for Capricor Therapeutics, Inc..

Ownership

Review ownership context for Capricor Therapeutics, Inc..

Other information

Review other information context for Capricor Therapeutics, Inc..

Community

Review community context for Capricor Therapeutics, Inc..